Varicella Zoster Virus (VZV) Antibody, IgG, Serum
Varicella (chickenpox) and herpes varicella zoster (shingles) are caused by infection with the varicella-zoster virus (VZV), a herpes virus. Primary VZV infection is a highly contagious disease characterized by mild skin vesicles and/or rash. VZV affects nearly 4 million children and adults in the United States each year. The Varicella form of the disease produces vesicular pruritic (itchy) lesions. Lesions appear over a period of 2 - 4 days. The disease is most common in children, and symptoms include malaise, pharyngitis, rhinitis, and fever, and can cause more severe and painful illness in adults. Varicella can pose a serious threat to fetuses, neonates, and to non-immune or immunocompromised children and adults. It is important to monitor health care workers in areas with immunocompromised and pregnant patients in order to avoid spread of the virus.
After primary infection, VZV remains dormant in dorsal root and cranial nerve ganglia cells, a type of nerve cell. VZV can become reactivated in the form of zoster (shingles) and generally occurs in older adults whose cellular immunity has waned, the very young, and those with an impaired immune system. A rapid diagnosis is particularly valuable because effective drug therapy is available. Upon reactivation, the virus travels from the ganglion cells to the skin via the associated nerve, and there produces the rash. Reactivations occur in crops of lesions associated with one or more dermatomes.
VZV can cause birth defects or post-delivery complications, but is rare. VZV IgG antibodies can be detected as early as nine days after the onset of rash in varicella, 10 days in zoster. Immunoreactivity peaks at an average 66 days for varicella and 27 days for zoster. The IgM response to varicella is detected at 6-7 days post-onset and peaks at an average 14 days; IgM response to zoster is detectable at 8 - 10 days and peaks at 18 - 19 days.
The IgG test is intended for the detection and quantitative determination of antibody to VZV in human serum. Positive results in neonates must be interpreted with caution, because maternal IgG is transferred passively from the mother to the fetus before birth.
IgM assays are generally more useful indicators of infection in children less than 6 months of age. Samples collected very early in the course of an infection (within 5 days after onset of rash) may not have detectable levels of VZV IgG. In such cases, it is recommended that the patient be tested for VZV IgM.
- Serological determination of past, recent, or current infection
- Assessment of serological status to VZV in pregnant women and neonates
- Aid in the diagnosis of disease caused by varicella-zoster virus
Positive in:
- Patient with immunity to VZV
- Patient with exposure to VZV
- Patients with recent or remote infection with VZV
Negative in:
- Individuals who have never been infected with VZV
Negative (Non-reactive) or <0.9 index value
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum (SST), cerebrospinal fluid (CSF).
-
Stability (serum)
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
Stability (CSF)
- Ambient: 1-3 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Ann Intern Med. 1999 Jun 1;130(11):922-32. [PMID: 10375341]
- J Infect Dis. 2008 Mar 1;197 Suppl 2:S147-51. [PMID: 18419389]
- Clin Microbiol Rev. 1996 Jul;9(3):361-81. [PMID: 8809466]
- Med Microbiol Immunol. 2007 Jun;196(2):95-102. [PMID: 17180380]
- J Infect Dis. 1994 Oct;170(4):991-5. [PMID: 7930746]
- J Perinatol. 2000 Dec;20(8 Pt 1):548-54. [PMID: 11190597]